General Information |
| Clinical trials phase |
Phase 2 |
| Start date (estimated) |
2024-12-19 |
| End date (estimated) |
2026-12-15 |
| Clinical feature |
| Label |
Sarcopenia |
| Link |
http://purl.obolibrary.org/obo/NCIT_C186726 |
| Description |
A reduction in muscle mass and function that is associated with aging or disuse. |
|
Administrative Information |
| NCT number |
NCT06600581 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT06600581 |
| Source weblink |
https://clinicaltrials.gov/study/NCT06600581 |
| Sponsors |
Immunis, Inc.
|
Cells |
| Which differentiated cell type is used |
| Label |
Secretome |
| Link |
http://id.nlm.nih.gov/mesh/D000089282 |
| Description |
The set of all the soluble factors and extracellular vesicles secreted into the extracellular space by cells, or an organ or organism. In some studies the secretome only refers to the proteins secreted into the extracellular space. |
|
Recruitment |
| Recruitment Status |
Recruiting |
| Estimated number of participants |
55 |
